There are 2934 resources available
4175 - Extra-pulmonary (EP) high grade (HG) neuroendocrine carcinoma (NEC): real-life outcomes of fifty-eight patients from a Portuguese cancer center.
Presenter: Rita Conde
Session: Poster Display session 2
Resources:
Abstract
3274 - Efficacy of immune check-point inhibitors (ICPi) in large cell neuroendocrine tumors of lung (LCNET)
Presenter: Shira Sherman
Session: Poster Display session 2
Resources:
Abstract
2820 - Analytical validation of a thyroid cancer diagnostic method based on the relative quantification of CLDN10, HMGA2 and LAMB3 expression
Presenter: Mateus Barrosfilho
Session: Poster Display session 2
Resources:
Abstract
Refining the treatment landscape of advanced prostate cancer
Presenter: Nicolas Mottet
Session: Janssen Pharmaceutical Companies of Johnson & Johnson - Expanding the therapeutic opportunities in advanced prostate cancer
Resources:
Webcast
Optimising therapeutic strategies in mHSPC
Presenter: Alvaro Pinto Marin
Session: Janssen Pharmaceutical Companies of Johnson & Johnson - Expanding the therapeutic opportunities in advanced prostate cancer
Resources:
Webcast
nmCRPC: Practical identification and current management of patients with nmCRPC
Presenter: Laura-Maria Krabbe
Session: Janssen Pharmaceutical Companies of Johnson & Johnson - Expanding the therapeutic opportunities in advanced prostate cancer
Resources:
Webcast
Understanding advances and defining next steps
Presenter: Eleni Efstathiou
Session: Janssen Pharmaceutical Companies of Johnson & Johnson - Expanding the therapeutic opportunities in advanced prostate cancer
Resources:
Webcast
3446 - Fluoropyrimidine-induced cardiotoxicity in colorectal cancer patients: preliminary data from the prospective observational CHECKPOINT trial (NCT02665312)
Presenter: Pasquale Lombardi
Session: Poster Display session 2
Resources:
Abstract
3969 - Comparable survival outcome between Thai patients with sporadic young adult and adult onset colorectal cancer
Presenter: Kanjana Sukhokanjanachusak
Session: Poster Display session 2
Resources:
Abstract
4455 - Impact of primary tumor side on 3-year survival outcomes of first-line (1L) FOLFOX-4 ± cetuximab in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 3 TAILOR trial
Presenter: Shukui Qin
Session: Poster Display session 2
Resources:
Abstract